Lv54
989 积分 2023-07-13 加入
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
22小时前
已完结
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
1天前
已完结
861-P: Targeting Activin Type II Receptors—Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction
2天前
求助中
PCSK9 MONOCLONAL ANTIBODY RECATICIMAB IN ADULT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (REMAIN-3): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY
3天前
已完结
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
3天前
已完结
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
4天前
已完结
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
5天前
已完结
Comparison of Usefulness of Body Mass Index Versus Metabolic Risk Factors in Predicting 10-Year Risk of Cardiovascular Events in Women
8天前
已关闭
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
8天前
已完结
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
9天前
已完结
皖公网安备34019202002308
